Rivaroxaban

A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.

Also Known As:

Networked: 4225 relevant articles (376 outcomes, 1222 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Berkowitz, Scott D: 103 articles (11/2022 - 05/2009)
2.	Lip, Gregory Y H: 103 articles (09/2022 - 03/2007)
3.	Fox, Keith A A: 90 articles (12/2022 - 06/2008)
4.	Patel, Manesh R: 68 articles (01/2022 - 06/2008)
5.	Coleman, Craig I: 63 articles (01/2022 - 09/2012)
6.	Hankey, Graeme J: 57 articles (10/2021 - 09/2011)
7.	Beyer-Westendorf, Jan: 56 articles (01/2022 - 01/2013)
8.	Mahaffey, Kenneth W: 56 articles (01/2022 - 06/2008)
9.	Halperin, Jonathan L: 55 articles (10/2022 - 09/2011)
10.	Eikelboom, John W: 54 articles (12/2022 - 01/2011)

Related Diseases

1.	Hemorrhage 03/05/2020 - "According to the subgroup analysis in the COMPASS study, supplementing ASA with rivaroxaban 2.5 mg, b.i.d., may appear most beneficial for patients with stable atherosclerotic disease and with a high risk of severe CVC without causing an increased risk of bleeding." 02/15/2013 - "However, the phase III trial of low-dose rivaroxaban demonstrated a significantly reduced incidence of recurrent vascular events without an increased risk of fatal bleeding. " 01/01/2021 - "Although effective in preventing VTE, bleeding remains relatively high in Rivaroxaban. " 02/01/2019 - "Rivaroxaban has an improved safety profile in patients with moderate renal dysfunction due to a significantly lower incidence of major bleeding. " 01/01/2009 - "Notably, the superior efficacy of rivaroxaban was achieved with a low but not significant increase in the incidence of major bleeding episodes. "
2.	Stroke (Strokes) 04/20/2016 - "The established efficacy and safety profile of rivaroxaban, together with its convenient once-daily dosing schedule, may contribute to improved patient outcomes and lead to sustained benefits for patients with non-valvular AF at risk of stroke." 09/28/2016 - "Data from these studies present collaborative efforts to build upon existing registrational Phase III data for rivaroxaban, driving the need for effective and safe treatment of a wider range of patients for stroke prevention." 01/01/2016 - "Results of one year of observation of 6784 patients confirmed that rivaroxaban is effective and safe in real unselected population of patients with non-valvular AF and various stroke risk. " 08/01/2023 - "The study population comprises consecutively screened, consenting patients with NVAF naïve to and newly treated with rivaroxaban for stroke prevention in routine clinical practice. " 08/01/2023 - "The RITMUS-AF study aims to evaluate the persistence with rivaroxaban treatment for stroke prevention in patients with NVAF in Italy. "
3.	Atrial Fibrillation 02/01/2018 - "These results suggest that rivaroxaban is effective and safe in extreme elderly patients with atrial fibrillation." 01/01/2023 - "Safety and Efficacy of Cryoballoon Pulmonary Vein Isolation and Left Atrial Appendage Closure Combined Procedure and Half-Dose Rivaroxaban After Operation in Elderly Patients with Atrial Fibrillation." 11/01/2014 - "The postmarketing surveillance registry evaluated the safety and efficacy of rivaroxaban in Japanese patients with atrial fibrillation (AF) treated with rivaroxaban. " 09/01/2014 - "The efficacy of rivaroxaban in patients with atrial fibrillation." 01/01/2013 - "Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation: subanalysis of J-ROCKET AF for patients with moderate renal impairment."
4.	Venous Thromboembolism 01/01/2011 - "Our study demonstrates the need for further randomised controlled clinical trials to be conducted to assess the safety and efficacy of rivaroxaban in clinical practice, focusing on the surgical complications as well as the potential prevention of venous thromboembolism." 04/01/2018 - "For venous thromboembolism (VTE) treatment, patient satisfaction was shown to improve with rivaroxaban versus standard anticoagulation in the phase III EINSTEIN DVT and EINSTEIN PE trials. " 01/01/2010 - "At present, the safety and efficacy of rivaroxaban for the prophylaxis and treatment of venous thromboembolism has been evaluated in phase-II and phase-III trials involving over 24,000 patients. " 06/01/2008 - "At present, the safety and efficacy of rivaroxaban for the prophylaxis and treatment of venous thromboembolism has been evaluated in Phase II and Phase III trials involving over 24,000 patients. " 10/20/2022 - "Safety and Efficacy of Rivaroxaban for Extended-Phase Anticoagulation of Patients with Unprovoked or Recurrent Venous Thromboembolism: Real-Life Data from the MAC Project."
5.	Thrombosis (Thrombus) 06/01/2022 - "Rivaroxaban for IVC thrombosis after successful CDT can be safe and effective." 03/01/2013 - "Whole blood clots are more resistant to lysis than plasma clots--greater efficacy of rivaroxaban." 01/01/2023 - "The use of rivaroxaban appears to be safe and effective in the prevention of thrombosis in a pediatric patient with CAA." 06/01/2022 - "This study aimed at investigating the safety and efficacy of rivaroxaban for IVC thrombosis after CDT. " 01/01/2020 - "The aim of this study was assess the efficacy of increased dose of rivaroxaban (15 mg twice daily) treatment for lysis of thrombus in the LAA. "

Related Drugs and Biologics

1.	Warfarin (Coumadin)
2.	apixaban
3.	Dabigatran
4.	Anticoagulants
5.	Enoxaparin (Lovenox)
6.	Aspirin (Acetylsalicylic Acid)
7.	Factor Xa Inhibitors
8.	edoxaban
9.	Vitamin K
10.	Factor Xa (Coagulation Factor Xa)

Related Therapies and Procedures

1.	Therapeutics
2.	Knee Replacement Arthroplasty (Total Knee Replacement)
3.	Secondary Prevention
4.	Hip Replacement Arthroplasty (Total Hip Replacement)
5.	Catheter Ablation